Small cell lung cancer (SCLC) is an aggressive form of lung cancer characterized by dismal
prognosis. Although SCLC may initially respond well to platinum-based chemotherapy, it …

In the past 10 years, a deeper understanding of the immune landscape of cancers, including
immune evasion processes, has allowed the development of a new class of agents. The …

There are several interactions within the tumor microenvironment (TME) that affect the
response of cancer cells to therapy. There are also a large number of cells and secretions in …

Small cell lung cancer (SCLC) is a highly malignant tumor with extremely poor prognosis.
The treatment strategy is very limited, and patient outcomes remain dismal with the 5-year …

Worldwide, non-small cell lung cancer (NSCLC) has the highest morbidity and mortality of
all malignancies. The lack of responsiveness to checkpoint inhibitors is a central problem in …

Highlights•ICIs have shifted the treatment paradigm to improve overall survival in advanced
SCLC.•The magnitude of immune-chemotherapy strategy is still modest. The …

Small-cell lung cancer (SCLC) is a very aggressive neuroendocrine tumor with a poor
prognosis. Whereas immunotherapy has emerged as a promising approach for treating …

Abstract Objectives In the Phase I/III IMpower133 study, first-line atezolizumab plus
carboplatin and etoposide (CP/ET) treatment for extensive-stage small cell lung cancer (ES …

Lung adenocarcinoma (LUAD) is the most common malignancy, leading to more than 1
million related deaths each year. Due to low long-term survival rates, the exploration of …

Small cell lung cancer (SCLC) represents about 13%–15% of all lung cancers. It has a
particularly unfavorable prognosis and in about 70% of cases occurs in the advanced stage …